Payment overview · 2025
General Payments
$741.97
25 reported records · 11 companies
Healthcare provider profile · identity verified
Farah K Soliman, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · TALLAHASSEE, FL · NPI 1316154602
Verified facts
What the public records show
CMS Open Payments records show Farah K Soliman, M.D. received $741.97 in general payments during 2025 across 25 reported records.
Medtronic, Inc. accounted for 25.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 17 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Jardiance, Mounjaro.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 57 claims for Synthroid by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 65 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 44 claims for Mounjaro by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 213 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 17 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 208 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$190.97 | 25.7% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $112.30 | 15.1% | 5 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $96.25 | 13.0% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $77.74 | 10.5% | 4 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $70.55 | 9.5% | 4 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $46.64 | 6.3% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $45.59 | 6.1% | 2 | 2025 |
| Dynavax Technologies Corporation | Unresolved — no canonical attribution shown | $34.68 | 4.7% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $31.41 | 4.2% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $20.81 | 2.8% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $15.03 | 2.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $741.97 | 25 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MO.MA ULTRA Normalized: mo ma ultra |
Device | Medtronic, Inc. | $190.97 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $112.30 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $96.25 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc., Lilly USA, LLC | $61.93 | 3 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $45.59 | 2 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $38.71 | 2 | 2025 |
Source payment records
|
|||||
| Heplisav-B Normalized: heplisav b |
Drug | Dynavax Technologies Corporation | $34.68 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $32.11 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $31.84 | 2 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $23.28 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $20.81 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $16.12 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.27 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 208 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 65 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 44 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
57 | 17 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
65 | 18 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
44 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
213 | 40 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
17 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
208 | 47 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
36 | 34 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 599 | 152 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 565 | 165 |
| Levothyroxine Sodium | Levothyroxine Sodium | 468 | 122 |
| Amlodipine Besylate | Amlodipine Besylate | 394 | 103 |
| Losartan Potassium | Losartan Potassium | 366 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 294 | 75 |
| Metformin Hcl | Metformin Hcl | 254 | 73 |
| Pantoprazole Sodium | Pantoprazole Sodium | 227 | 72 |
| Lisinopril | Lisinopril | 222 | 61 |
| Ozempic | Semaglutide | 213 | 40 |
| Eliquis | Apixaban | 208 | 47 |
| Omeprazole | Omeprazole | 207 | 55 |
| Gabapentin | Gabapentin | 163 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 155 | 38 |
| Tamsulosin Hcl | Tamsulosin Hcl | 134 | 33 |
| Ezetimibe | Ezetimibe | 131 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 124 | 33 |
| Alprazolam | Alprazolam | 123 | 25 |
| Metoprolol Tartrate | Metoprolol Tartrate | 122 | 30 |
| Metformin Hcl Er | Metformin Hcl | 114 | 33 |
| Simvastatin | Simvastatin | 114 | 30 |
| Allopurinol | Allopurinol | 107 | 29 |
| Atenolol | Atenolol | 106 | 28 |
| Pravastatin Sodium | Pravastatin Sodium | 104 | 30 |
| Potassium Chloride | Potassium Chloride | 100 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 99 | 29 |
| Furosemide | Furosemide | 99 | 33 |
| Citalopram Hbr | Citalopram Hydrobromide | 98 | 18 |
| Tizanidine Hcl | Tizanidine Hcl | 90 | 40 |
| Bupropion Xl | Bupropion Hcl | 85 | 18 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 83 | 34 |
| Irbesartan | Irbesartan | 80 | 18 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 80 | 26 |
| Duloxetine Hcl | Duloxetine Hcl | 78 | 15 |
| Trazodone Hcl | Trazodone Hcl | 78 | 21 |
| Celecoxib | Celecoxib | 72 | 25 |
| Famotidine | Famotidine | 68 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 68 | 23 |
| Donepezil Hcl | Donepezil Hcl | 67 | 13 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 67 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 66 | 12 |
| Jardiance | Empagliflozin | 65 | 18 |
| Sertraline Hcl | Sertraline Hcl | 63 | 17 |
| Tramadol Hcl | Tramadol Hcl | 63 | 21 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 62 | 50 |
| Montelukast Sodium | Montelukast Sodium | 61 | 16 |
| Carvedilol | Carvedilol | 59 | 20 |
| Meloxicam | Meloxicam | 59 | 18 |
| Synthroid | Levothyroxine Sodium | 57 | 17 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 39 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | suppressed |
| Glimepiride | Glimepiride | 55 | 16 |
| Clonidine Hcl | Clonidine Hcl | 53 | 11 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 52 | 14 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 50 | 11 |
| Memantine Hcl | Memantine Hcl | 50 | suppressed |
| Azithromycin | Azithromycin | 48 | 42 |
| Farxiga | Dapagliflozin Propanediol | 47 | 16 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 13 |
| Mounjaro | Tirzepatide | 44 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 43 | suppressed |
| Estradiol | Estradiol | 42 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 41 | suppressed |
| Xarelto | Rivaroxaban | 41 | suppressed |
| Lidocaine | Lidocaine | 40 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 39 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 38 | 13 |
| Ramipril | Ramipril | 38 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 37 | 22 |
| Ibandronate Sodium | Ibandronate Sodium | 37 | 13 |
| Pregabalin | Pregabalin | 37 | 11 |
| Paxlovid | Nirmatrelvir/Ritonavir | 36 | 34 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 35 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 32 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 32 | 15 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 31 | suppressed |
| Lorazepam | Lorazepam | 31 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 30 | suppressed |
| Candesartan Cilexetil | Candesartan Cilexetil | 30 | suppressed |
| Lamotrigine | Lamotrigine | 30 | suppressed |
| Clonazepam | Clonazepam | 29 | suppressed |
| Ondansetron Odt | Ondansetron | 29 | 18 |
| Spironolactone | Spironolactone | 29 | suppressed |
| Lansoprazole | Lansoprazole | 28 | suppressed |
| Ibuprofen | Ibuprofen | 27 | 13 |
| Januvia | Sitagliptin Phosphate | 26 | suppressed |
| Mirtazapine | Mirtazapine | 26 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 25 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | 15 |
| Diclofenac Sodium | Diclofenac Sodium | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Temazepam | Temazepam | 23 | suppressed |
| Valsartan | Valsartan | 23 | suppressed |
| Diazepam | Diazepam | 22 | suppressed |
| Hydrocortisone | Hydrocortisone | 20 | 12 |
| Methylprednisolone | Methylprednisolone | 20 | 14 |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 19 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Finasteride | Finasteride | 18 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 18 | 13 |
| Quetiapine Fumarate Er | Quetiapine Fumarate | 18 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 17 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Levetiracetam | Levetiracetam | 17 | suppressed |
| Ranolazine Er | Ranolazine | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 16 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Digoxin | Digoxin | 16 | suppressed |
| Fluconazole | Fluconazole | 16 | 11 |
| Oxcarbazepine | Oxcarbazepine | 16 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 16 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 15 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 15 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Aripiprazole | Aripiprazole | 14 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate | 14 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 14 | suppressed |
| Fluvoxamine Maleate | Fluvoxamine Maleate | 14 | suppressed |
| Gemfibrozil | Gemfibrozil | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 14 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 14 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 14 | suppressed |
| Fentanyl | Fentanyl | 13 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 13 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 13 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Myrbetriq | Mirabegron | 11 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 11 | suppressed |
| Phenobarbital | Phenobarbital | 11 | suppressed |
| Torsemide | Torsemide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $741.97 · 25 records | Medtronic, Inc. | ELIQUIS, ENTRESTO, EVENITY, GEMTESA, Heplisav-B, JARDIANCE, Kerendia, LEQVIO, MO.MA ULTRA, MOUNJARO, NURTEC ODT, OTEZLA, QULIPTA, REPATHA, UBRELVY, Wegovy, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error